4D Molecular Therapeutics, Inc.
FDMTNasdaqCIK 1650648HealthcareFiscal year ends Dec 31
Reports and events: 100 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2812:05 ET | 8-K | 8.01 Other events | 0001193125-26-403424 |
| 2026-08-1320:09 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-349173 |
| 2026-08-1320:06 ET | 8-K | 2.02 Results of operations | 0001193125-26-349160 |
| 2026-07-2012:30 ET | 8-K | 8.01 Other events | 0001193125-26-308409 |
| 2026-06-2912:05 ET | 8-K | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-286880 |
| 2026-06-2220:21 ET | 8-K | 5.07 Shareholder vote results | 0001193125-26-277563 |
| 2026-05-0720:13 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-211939 |
| 2026-05-0720:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-211904 |
| 2026-04-2820:05 ET | DEF 14A | Proxy statementPeriod 2026-06-17 | 0001140361-26-017427 |
| 2026-03-3021:29 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-131739 |
| 2026-03-1820:29 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-114075 |
| 2026-03-1820:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-113949 |
| 2026-01-2621:05 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-022559 |
| 2026-01-0713:05 ET | 8-K | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors | 0001193125-26-005470 |
| 2025-12-1021:06 ET | 8-K | 8.01 Other events | 0001193125-25-314167 |
| 2025-11-1711:05 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-283861 |
| 2025-11-1013:19 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-273343 |
| 2025-11-1013:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-273340 |
| 2025-11-0721:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-25-272286 |
| 2025-11-0611:02 ET | 8-K | 2.02 Results of operations; 8.01 Other events | 0001193125-25-267934 |
| 2025-10-3110:02 ET | 8-K | 1.01 Entry into a material agreement | 0001193125-25-259302 |
| 2025-10-0220:04 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-228289 |
| 2025-08-1112:07 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-106244 |
| 2025-08-1112:05 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-106243 |
| 2025-07-0220:12 ET | 8-K | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0000950170-25-092964 |
| 2025-06-2020:03 ET | 8-K | 5.07 Shareholder vote results | 0000950170-25-088482 |
| 2025-05-0820:21 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-067040 |
| 2025-05-0820:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-067013 |
| 2025-04-2920:05 ET | DEF 14A | Proxy statementPeriod 2025-06-17 | 0001140361-25-016307 |
| 2025-02-2821:27 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-030056 |
| 2025-02-2821:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-030020 |
| 2025-02-1013:37 ET | 8-K | 8.01 Other events | 0000950170-25-016708 |
| 2025-01-1013:36 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-003832 |
| 2024-12-1121:15 ET | 8-K | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0000950170-24-135381 |
| 2024-11-1321:27 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-126370 |
| 2024-11-1321:17 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-126346 |
| 2024-09-1820:06 ET | 8-K | 8.01 Other events | 0001193125-24-221375 |
| 2024-08-0820:15 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-094010 |
| 2024-08-0820:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-093992 |
| 2024-07-2310:04 ET | 8-K | 7.01 Regulation FD disclosure | 0001193125-24-182544 |
| 2024-07-1710:04 ET | 8-K | 8.01 Other events | 0001193125-24-179950 |
| 2024-06-0721:07 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-24-157521 |
| 2024-05-2420:28 ET | 8-K | 5.07 Shareholder vote results | 0001193125-24-147093 |
| 2024-05-0920:22 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-057035 |
| 2024-05-0920:09 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056933 |
| 2024-04-1020:05 ET | DEF 14A | Proxy statementPeriod 2024-05-21 | 0001140361-24-019090 |
| 2024-02-2921:38 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-023183 |
| 2024-02-2921:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-023088 |
| 2024-02-0921:56 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-030203 |
| 2024-01-0413:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-001977 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:14 ET. Listed shows no prices and gives no investment advice.